Large trial finds ticlopidine superior to aspirin in preventing stroke

Article Abstract:

Ticlopidine hydrochloride appears to be superior to aspirin in its ability to prevent stroke among high risk patients. Either ticlopidine or aspirin was administered to patients who had suffered from transient ischemic attack (temporary interruption of blood supply to the brain) in a study of the effectiveness of these two drugs at preventing stroke. Patients receiving ticlopidine suffered 21 percent fewer fatal and nonfatal strokes than did patients who received aspirin as a prophylaxis against stroke. Syntex Corp. (Palo Alto, CA.), the manufacturer of ticlopidine, expects the retail price of the drug to be in the range of $1 to $2 per day, which is substantially more than the cost of using aspirin as a stroke-preventing agent. Despite the high cost of the drug, ticlopidine appears to offer stroke-preventing benefits to women as well as men, while aspirin does not appear as effective at preventing strokes among women. Physicians are not ready to abandon aspirin: until future studies indicate otherwise, aspirin will remain the drug of choice for stroke prophylaxis in the majority of cases. Several studies investigating ticlopidine use as a stroke-preventing agent for high-risk patients are being conducted and medical professionals are awaiting the outcome of these studies.

Cerebrovascular disease, Cerebrovascular disorders

---

Prevention of a First Stroke: A Review of Guidelines and a Multidisciplinary Consensus Statement From the National Stroke Association

Article Abstract:

There are many effective ways of preventing a stroke. Strokes occur when a blood clot in the brain cuts off the blood supply to part of the brain. Hypertension is a risk factor, so patients with high blood pressure should be treated. A heart disease called atrial fibrillation can cause blood clots, and these patients can take anticoagulant drugs. Patients with carotid artery disease may benefit from surgery that removes the fatty deposits lining the arteries. Patients can also make dietary changes, stop smoking and using alcohol and exercise on a regular basis.

---

Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial

Article Abstract:

Aspirin may be better than ticlopidine for preventing a second stroke in African-American stroke patients, according to a study of 1,809 men and women. Although both drugs reduced the risk of a second stroke to about the same degree, aspirin has fewer side effects than ticlopidine. Aspirin and ticlopidine are both anticoagulants, which are drugs that prevent blood clots.

Pharmaceutical Preparation Manufacturing, Pharmaceutical preparations, Aspirin, Aspirin Combinations, Health aspects, Care and treatment, African Americans

Similar abstracts:

• Abstracts: Lightning strikes twice: electricity from two directions may give superior pain relief. Iliotibial band friction syndrome: early detection the key to avoiding knee pain
• Abstracts: Market induces a new approach to capitation: prepayment for specialists, fee for service for generalists. Locum tenens evolving into local placement service
• Abstracts: Coalition presses to preserve affirmative action in medicine. Ready or not, here are outcomes 'report cards.' (outcomes research)
• Abstracts: The incidence of perioperative myocardial infarction in men undergoing noncardiac surgery. Hospital use and survival among Veterans Affairs beneficiaries
• Abstracts: Hemodynamic and fluid responses to furosemide infusion in the ovine fetus. Regulation of amniotic fluid volume by intramembranous absorption in sheep: role of passive permeability and vascular endothelial growth factor

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.